USTR Opens Section 301 Investigation into Germany's Drug Pricing, Tariffs on the Table

What Happened

On June 18, 2026, USTR Jamieson Greer formally opened a Section 301 investigation into Germany's pharmaceutical pricing policies, according to the official USTR press release. The investigation will examine whether Germany's reimbursement practices for innovative medicines are "unreasonable or discriminatory" and whether they burden U.S. commerce.

The action is the first step in a process that could lead to tariff announcements.

The U.S. Argument

Washington's core complaint: German price controls on drugs keep reimbursement rates artificially low, meaning American companies recoup far less revenue from the German market than the drugs cost to develop. U.S. patients, through higher domestic prices, effectively make up the gap.

"President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development," Greer said in the USTR statement.

Adding urgency to the probe: Germany is reportedly fast-tracking legislation that would reduce its pharmaceutical spending further. Greer called that "a serious step backwards."

Just two days before the announcement, on June 16, 23 Senate Republicans sent a letter urging the administration to act against foreign drug pricing practices, according to Crypto Briefing's reporting on the investigation.

What Section 301 Actually Does

Section 301 of the Trade Act of 1974 gives USTR authority to investigate foreign trade practices it deems unreasonable, unjustifiable, or discriminatory, and then impose tariffs or other trade restrictions if the investigation finds merit. The U.S. used this authority in 2018 to impose tariffs on hundreds of billions of dollars in Chinese goods, as Crypto Briefing noted.

A public comments docket opens June 25. A formal public hearing is scheduled for September 22.

This investigation is also part of a broader wave of 2026 Section 301 actions. According to the USTR's own release, the agency has simultaneously made findings in 60 separate Section 301 investigations related to forced labor trade practices and has opened a separate Section 301 determination against Brazil. Germany's pharmaceutical probe is not an isolated action.

Months of Talks First

All three sources confirm that this investigation follows months of bilateral negotiations between U.S. and German officials that failed to produce a resolution. The USTR described the prior engagement as "meaningful discussions." Anadolu Ajansı's June 19 reporting characterized them as discussions "aimed at resolving concerns over pharmaceutical pricing and reimbursement" that did not result in an agreement.

The probe represents escalation after diplomacy stalled.

The Strongest Counter-Argument

Germany's defenders, and there are reasonable ones, argue that government drug price negotiation is a legitimate exercise of a sovereign nation's healthcare policy, not a trade violation. Every developed country controls pharmaceutical costs in some form. Germany's system, the Arzneimittelmarktneuordnungsgesetz (AMNOG), evaluates the added benefit of new drugs before setting reimbursement rates. Critics of the U.S. position say Washington is essentially demanding that allied governments pay higher prices to protect American corporate profit margins, and that framing this as a trade burden on U.S. patients is a political sleight of hand: American drug prices are high because of U.S. domestic policy choices, not German ones.

The USTR's counter is that the cumulative effect of price controls across multiple allied markets does shift R&D cost recovery disproportionately onto the U.S. market. Whether that constitutes an actionable trade burden under Section 301 is precisely what the investigation is designed to determine.

What's Actually at Stake

If USTR ultimately finds Germany's practices harm U.S. commerce, retaliatory tariffs on German pharmaceutical exports become a concrete option, according to Crypto Briefing's analysis. Trade measures could also restrict market access for drugs flowing in either direction.

For major U.S. pharmaceutical companies, a favorable ruling could eventually force higher reimbursement rates in Germany and potentially pressure similar pricing structures elsewhere in the EU. The European Union could respond with its own retaliatory measures against U.S. goods or services.

Germany is a NATO ally and one of the U.S.'s largest trading partners in Europe. Opening a Section 301 action against Berlin while simultaneously managing tariff disputes with the broader EU adds another pressure point to an already complicated transatlantic relationship.

What Comes Next

The procedural calendar is set: public comment period opens June 25, formal hearing September 22. Whether those proceedings produce a negotiated settlement—Germany adjusting its pricing framework in exchange for the U.S. dropping the probe—or escalate to proposed tariffs depends heavily on whether Berlin's fast-tracked legislation actually becomes law and how far it moves before September. That legislative timeline in Germany is the variable neither the USTR release nor the media sources have pinned down with specificity.